Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

PURPOSE: Patients with hormone receptor–negative breast cancer generally do not benefit from endocrine-targeted therapies. However, a subset with androgen receptor (AR) expression is predicted to respond to antiandrogen therapies. This phase II study explored bicalutamide in AR-positive, estrogen re...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gucalp, Ayca, Tolaney, Sara, Isakoff, Steven J., Ingle, James N., Liu, Minetta C., Carey, Lisa A., Blackwell, Kimberly, Rugo, Hope, Nabell, Lisle, Forero, Andres, Stearns, Vered, Doane, Ashley S., Danso, Michael, Moynahan, Mary Ellen, Momen, Lamia F., Gonzalez, Joseph M., Akhtar, Arooj, Giri, Dilip D., Patil, Sujata, Feigin, Kimberly N., Hudis, Clifford A., Traina, Tiffany A.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4086643/
https://ncbi.nlm.nih.gov/pubmed/23965901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3327
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars